HCC and the need for new targets Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death worldwide. Current treatments including tyrosine kinase inhibitors and immune checkpoint inhibitors provide limited survival benefits, and resistance is common. New molecular targets are urgently needed.
Frequency of Wnt/beta-catenin alterations Comprehensive genomic analyses reveal that 30-40% of human HCCs show aberrant activation of the Wnt/beta-catenin pathway. CTNNB1 (encoding beta-catenin) gain-of-function mutations occur in 27% of HCC patients, while AXIN1 loss-of-function mutations occur in 8% and APC mutations in 3%.
Pathway mechanism In the absence of Wnt ligands, cytosolic beta-catenin is phosphorylated by a complex of APC and AXIN1 proteins, tagged for ubiquitination and proteasomal degradation. When Wnt ligands activate Frizzled receptors, this degradation complex is disrupted, allowing beta-catenin to accumulate and translocate to the nucleus where it activates target gene transcription via TCF/LEF transcription factors.
Multiple activation mechanisms Beyond direct mutations, Wnt/beta-catenin can be activated non-genetically in HCC through promoter methylation of the SFRP1 antagonist, overexpression of Frizzled receptors and Wnt ligands, and deregulated microRNAs and long noncoding RNAs that modulate pathway components.
Distinct clinical associations HCCs with beta-catenin activation have distinctive features: they occur more frequently in HCV-related and non-cirrhotic HCC, and are associated with the non-proliferation HCC subgroup (G5/G6 in Boyault classification, cluster 2 in TCGA classification). Most studies suggest CTNNB1 mutation is a favorable prognostic marker.
Characteristic histopathological features CTNNB1-mutated HCCs are typically large (>6 cm), solitary lesions showing microtrabecular and acinar growth patterns with high differentiation (Edmondson grade G1-G2), prominent cholestasis, and absence of steatosis and inflammation - features that help pathologists identify this molecular subtype.
Glutamine synthetase as a diagnostic marker Glutamine synthetase (GS), encoded by GLUL, is a direct Wnt/beta-catenin target gene. Robust and uniform GS immunohistochemical expression identifies CTNNB1-mutated HCCs with 90% sensitivity and 98% specificity - superior to cytoplasmic/nuclear beta-catenin staining (63% sensitivity, 98% specificity).
Target gene signatures CTNNB1-mutated HCCs robustly upregulate canonical Wnt target genes including GLUL, TBX3, AXIN2, LGR5, SP5, and OAT. These gene expression signatures provide molecular confirmation of pathway activation and can be detected from RNA sequencing data in both tissue and liquid biopsies.
Beta-catenin alone is insufficient Transgenic mice overexpressing activated beta-catenin develop hepatomegaly but not HCC. This indicates that beta-catenin activation alone does not drive liver tumor formation - a second oncogenic signal is required for full malignant transformation.
Key cooperating oncogenes Studies using hydrodynamic gene delivery in mice identified multiple oncogenes that cooperate with activated beta-catenin to induce HCC: c-Met (in approximately 10% of human HCCs), K-RasV12, activated Akt, LKB1, and mutant Nrf2/NFE2L2. CTNNB1 mutations rarely co-occur with AXIN1 or APC mutations, confirming mutual exclusivity.
TERT promoter co-mutations TERT promoter mutations frequently co-occur with CTNNB1 mutations in HCC, suggesting a synergistic effect. TERT mutations are among the earliest genetic events in HCC progression and may create a permissive cellular context for beta-catenin-driven oncogenesis.
Downstream effectors of beta-catenin Key downstream targets driving beta-catenin-dependent hepatocarcinogenesis include c-MYC (involved in glycolysis and sorafenib responsiveness), glutamine synthetase (enabling mTORC1 addiction), TBX3, and cyclin D1. These targets represent potential therapeutic nodes downstream of direct beta-catenin inhibition.
Cancer stem cell maintenance Wnt/beta-catenin signaling is the dominant pathway regulating cancer stem cell (CSC) self-renewal and tumorigenicity in HCC. Overexpression of beta-catenin increases CSC self-renewal and in vivo tumorigenicity, suggesting that beta-catenin-positive CSCs drive tumor initiation and recurrence.
Metastasis and progression Activated Wnt/beta-catenin is also implicated in HCC metastasis. The pathway promotes epithelial-mesenchymal transition, vascular invasion, and distant spread. Understanding the spatial and temporal regulation of beta-catenin during tumor progression could identify windows for therapeutic intervention.
Drug resistance mechanisms Activated Wnt/beta-catenin is associated with resistance to sorafenib and regorafenib, the main approved tyrosine kinase inhibitors for HCC. This resistance mechanism has significant clinical implications, as it may explain why a subgroup of CTNNB1-mutated HCC patients respond poorly to standard systemic therapies.
mTOR addiction in CTNNB1-mutated HCC CTNNB1-mutated HCCs show mTORC1 addiction through the GS/glutamine/phospho-mTOR-S2448 axis. This creates a synthetic dependency that could be exploited therapeutically - mTORC1 inhibitors might be particularly effective for CTNNB1-mutant, GS-positive HCCs.
Immune-excluded HCC phenotype CTNNB1-mutated HCCs are typically immunologically cold - they show low immune cell infiltration, low tumor mutational burden, and absence of PD-L1 expression. This creates an immune-excluded microenvironment that is intrinsically resistant to immune checkpoint inhibitors.
Mechanism of immune exclusion Active Wnt/beta-catenin signaling has been shown to impair dendritic cell recruitment and T cell infiltration into tumors through downstream targets that suppress chemokine production. This creates a fundamental conflict: the mutation that drives HCC in this subgroup also protects it from immune attack.
Clinical data on immunotherapy resistance The atezolizumab plus bevacizumab combination immunotherapy regimen (first-line HCC treatment) shows significantly lower efficacy in CTNNB1-mutated HCC. CTNNB1 mutation is an emerging biomarker for immune checkpoint inhibitor resistance and should be considered in treatment selection.
Alternative treatment strategies needed For CTNNB1-mutated HCC, alternative strategies are needed. Targeting the beta-catenin pathway itself, its cooperative oncogene partners, or its downstream dependencies (such as mTOR) may be more effective than immune checkpoint inhibitors in this molecular subtype.
Direct pathway inhibitors Multiple strategies have been explored to directly inhibit Wnt/beta-catenin signaling in HCC: small molecules blocking beta-catenin/TCF interaction, Porcupine inhibitors blocking Wnt ligand secretion, and antisense oligonucleotides targeting CTNNB1 mRNA. Several are in early clinical trials.
Challenges of direct targeting Beta-catenin plays essential roles in normal tissue maintenance, particularly in intestinal epithelium and liver homeostasis. Systemic beta-catenin inhibition risks serious toxicities. Liver-targeted delivery systems or approaches that exploit the oncogenic context specifically in tumor cells may be required.
Targeting cooperative pathways Since activated beta-catenin always cooperates with a second oncogene, targeting the cooperating partner rather than beta-catenin itself may be safer. Anti-c-Met antibodies or kinase inhibitors in combination with Wnt pathway inhibitors represent rational combination approaches for CTNNB1/c-Met co-activated HCCs.
Downstream target vulnerabilities The mTORC1 addiction of CTNNB1-mutated HCCs is a clinically actionable vulnerability. Everolimus and other mTOR inhibitors might be repurposed for this molecular subtype. Similarly, targeting c-MYC activity in beta-catenin-driven HCC through BET bromodomain inhibitors represents an emerging strategy.
Precision diagnostics Developing reliable non-invasive biomarkers (liquid biopsy-based CTNNB1 mutation detection, circulating GS levels) would enable identification of beta-catenin-activated HCC patients for targeted therapy trials without requiring tumor tissue.
Combinatorial therapeutic approaches Given the multistep nature of beta-catenin-driven HCC, rational combinations targeting beta-catenin with its downstream effectors, cooperative oncogenes, or tumor microenvironment signals will likely be required. Clinical trials testing these combinations are a priority.
Understanding epigenetic regulation Non-genetic mechanisms of Wnt/beta-catenin activation - including DNA methylation, miRNA regulation, and lncRNA control - represent additional therapeutic targets and resistance mechanisms that warrant further investigation.
Translating mouse models to humans The hydrodynamic gene delivery mouse models have been invaluable for understanding beta-catenin cooperativity in vivo. Next-generation models using patient-derived xenografts with CTNNB1 mutations, combined with single-cell profiling of their tumor microenvironments, will provide better platforms for testing new therapeutics.